Therapy for diffuse large B-cell lymphoma: getting personal
Mené sur 1 080 patients atteints d'un lymphome diffus à grandes cellules B (durée médiane de suivi : 46 mois), cet essai britannique de phase III compare, du point de vue de la survie globale, deux modalités d'administration du protocole R-CHOP (toutes les 2 ou 3 semaines)
In 1979, Jones and colleagues showed that CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) was superior to CVP (cyclophosphamide, vincristine, and prednisone) in treatment of patients with diffuse lymphomas. This early report probably included patients with not only what is currently called diffuse large B-cell lymphoma but also other distinct lymphoproliferative disorders including T-cell non-Hodgkin lymphoma and mantle cell lymphoma. Despite repeated attempts to improve...